Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.4000
-0.0250 (-5.88%)
Mar 31, 2025, 2:27 PM EDT - Market open

Bolt Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Revenue
7.697.885.731.260.23
Upgrade
Revenue Growth (YoY)
-2.36%37.48%354.68%445.46%7.44%
Upgrade
Cost of Revenue
57.4761.5473.1275.6640.36
Upgrade
Gross Profit
-49.78-53.67-67.39-74.4-40.13
Upgrade
Selling, General & Admin
18.4622.5322.9318.399.06
Upgrade
Operating Expenses
18.4622.5322.9318.399.06
Upgrade
Operating Income
-68.24-76.2-90.32-92.79-49.18
Upgrade
Interest & Investment Income
5.2672.220.280.2
Upgrade
Other Non Operating Income (Expenses)
----6.08-11.75
Upgrade
EBT Excluding Unusual Items
-62.98-69.2-88.1-98.59-60.73
Upgrade
Merger & Restructuring Charges
-3.34----
Upgrade
Asset Writedown
-1.47----
Upgrade
Other Unusual Items
4.68----
Upgrade
Pretax Income
-63.12-69.2-88.1-98.59-60.73
Upgrade
Net Income
-63.12-69.2-88.1-98.59-60.73
Upgrade
Net Income to Common
-63.12-69.2-88.1-98.59-60.73
Upgrade
Shares Outstanding (Basic)
383837332
Upgrade
Shares Outstanding (Diluted)
383837332
Upgrade
Shares Change (YoY)
0.98%1.21%12.54%1479.05%5.46%
Upgrade
EPS (Basic)
-1.65-1.83-2.36-2.97-28.89
Upgrade
EPS (Diluted)
-1.65-1.83-2.36-2.97-28.89
Upgrade
Free Cash Flow
-61.33-69.73-78.46-59.4-50.57
Upgrade
Free Cash Flow Per Share
-1.61-1.84-2.10-1.79-24.05
Upgrade
Operating Margin
-887.33%-967.45%-1576.56%-7364.13%-21290.91%
Upgrade
Profit Margin
-820.78%-878.58%-1537.75%-7824.68%-26289.18%
Upgrade
Free Cash Flow Margin
-797.53%-885.36%-1369.47%-4714.60%-21891.78%
Upgrade
EBITDA
-66.46-74.34-88.66-91.6-48.57
Upgrade
D&A For EBITDA
1.781.851.671.190.61
Upgrade
EBIT
-68.24-76.2-90.32-92.79-49.18
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q